Tourmaline Bio, Inc.
Tourmaline Bio, Inc. (TRML): 3 pipeline candidates · ~34 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
34.3 months
D/E 0.04 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Tourmaline Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$31.6M
Quarterly Burn
$20.3M
Runway
34.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| pacibekitug | Phase 2 |
| tour006 | Phase 2 |
| tour006 - | Phase 2 |
Frequently asked questions
How many drug candidates are in Tourmaline Bio, Inc.'s pipeline?
Tourmaline Bio, Inc. (TRML) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Tourmaline Bio, Inc.'s lead drug candidate?
Tourmaline Bio, Inc.'s most advanced tracked candidate is pacibekitug (Phase 2) for Thyroid eye disease (TED).
What is Tourmaline Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Tourmaline Bio, Inc. has approximately 34.3 months of cash runway.
Who is the CEO of Tourmaline Bio, Inc.?
Sandeep Kulkarni, M.D. is the chief executive officer of Tourmaline Bio, Inc. (TRML).
Get the full picture on Tourmaline Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.